Physician profile
Ramesh Vedula
NPI 1881630895
$4,254.62
in general payments reported to CMS, 2019-2025
48 companies · $1,405 in 2025
The $1,405 reported for 2025 was more than what 87% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $58.67 · 2021: $451 · 2022: $629 · 2023: $565 · 2024: $1,022 · 2025: $1,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,991.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $466.41 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $384.47 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $357.47 | 2023-2025 | Imfinzi, Lynparza, Enhertu |
| Janssen Biotech, INC. | $211.27 | 2023-2025 | Balversa, Erleada, Akeega |
| Pfizer INC. | $201.07 | 2021-2025 | |
| Rigel Pharmaceuticals, INC. | $195.92 | 2022-2025 | Rezlidhia, Tavalisse, Gavreto |
| Lilly USA, LLC | $151.17 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Seagen INC. | $139.93 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $138.80 | 2023-2024 | Orgovyx |
| Sobi, INC | $129.38 | 2022-2025 | |
| Incyte Corporation | $125.04 | 2021-2024 | Jakafi |
| Actelion Pharmaceuticals US, INC. | $125.00 | 2019 | |
| Tactile Systems Technology INC | $112.83 | 2022-2024 | Entre Plus, Flexitouch Plus |
| Sun Pharmaceutical Industries INC. | $106.86 | 2022-2023 | Yonsa, Odomzo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.31 | 2021-2024 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $97.03 | 2022-2024 | Fotivda |
| Takeda Pharmaceuticals U.S.A., INC. | $85.46 | 2021-2024 | Fruzaqla, Gattex |
| Astellas Pharma US INC | $79.04 | 2021-2025 | Xtandi |
| Caris Mpi, INC. | $71.91 | 2025 | Mi Cancer Seek |
| Tempus Ai, INC | $71.29 | 2025 | Xt Cdx |
| Glaxosmithkline, LLC. | $68.27 | 2023-2025 | Ojjaara, Shingrix |
| Beigene USA, INC. | $62.83 | 2024 | Brukinsa |
| Jazz Pharmaceuticals INC. | $61.37 | 2021-2025 | |
| Iovance Biotherapeutics, INC. | $60.37 | 2025 | Amtagvi |
| Myovant Sciences INC. | $51.63 | 2021-2022 | |
| Ge Healthcare | $41.07 | 2025 | |
| Daiichi Sankyo INC. | $37.54 | 2024-2025 | Datroway, Enhertu |
| Coherus Oncology, INC. | $37.46 | 2020-2025 | Loqtorzi |
| Celltrion USA INC. | $33.67 | 2023 | Vegzelma |
| Genmab U.S., INC. | $33.67 | 2025 | Tivdak |
| Eisai INC. | $32.64 | 2025 | |
| Genzyme Corporation | $32.57 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.50 | 2020-2025 | |
| Tersera Therapeutics LLC | $31.96 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $30.84 | 2021 | |
| Pharmacosmos Therapeutics INC. | $24.28 | 2024 | Cosela |
| Amneal Pharmaceuticals LLC | $24.09 | 2025 | Pemrydi Rtu |
| Invivyd INC | $23.85 | 2025 | Pemgarda |
| Abbvie INC. | $23.84 | 2025 | |
| Acrotech Biopharma INC. | $21.63 | 2025 | Beleodaq |
| Beone Medicines USA, INC. | $21.45 | 2025 | Brukinsa |
| Siemens Medical Solutions USA, INC. | $19.43 | 2022 | |
| Teleflex LLC | $18.24 | 2025 | Barrigel |
| Genentech USA, INC. | $17.81 | 2024 | Kadcyla, Phesgo, Perjeta |
| Sirtex Medical INC | $16.43 | 2024 | Sir-Spheres Microspheres |
| Mirati Therapeutics, INC. | $15.89 | 2024 | Krazati |
| Myriad Genetic Laboratories, INC. | $14.58 | 2022 | |
| Dova Pharmaceuticals | $14.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramesh Vedula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.